Recent advances in therapeutic strategies for triple-negative breast cancer

Table 3 Ongoing clinical trials aimed at androgen receptor-positive TNBC

Drugs	Pharmacological mechanism	Register ID	Phase	Status
Bicalutamide	AR antagonists	NCT02348281	II	Terminated
		NCT03055312	III	Terminated
		NCT02353988	II	Unknown
Enzalutamide	AR pathway inhibitors	NCT02689427	IIb	Recruiting
Enzalutamide	AR pathway inhibitors	NCT02750358	II	Active
Seviteronel	A potent CYP17 lyase inhibitor	NCT02130700	II	Completed
Seviteronel	A potent CYP17 lyase inhibitor	NCT02580448	I/II	Completed
MK-2866	A nonsteroidal selective AR modulator	NCT02368691	I	Terminated
Darolutamide	Competitively inhibiting AR binding, translocation, and transcription	NCT03383679	II	Recruiting
Dehydroepiandrosterone	Intermediates of steroid hormones	NCT00972023	I	Terminated
Orteronel	CYP17 inhibitors	NCT01990209	II	Active

ISSN: 1756-8722